Allogene Therapeutics (ALLO) Net Income towards Common Stockholders (2018 - 2026)
Allogene Therapeutics (ALLO) posted Net Income towards Common Stockholders of -$145.2 million for Q1 2026, down 185.38% sequentially from -$50.9 million in Q4 2025, and down 96.88% YoY from -$4.7 billion in Q1 2025.
Allogene Therapeutics (ALLO) Net Income towards Common Stockholders (2018 - 2026) Analysis & Trends
Allogene Therapeutics has reported Net Income towards Common Stockholders for 9 years, with the latest figure at -$145.2 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 96.88% year-over-year to -$145.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$337.7 million (up 16.0% YoY) and the FY2025 annual result came in at -$190.9 million, up 25.9% from the prior year.
- Net Income towards Common Stockholders slipped to -$145.2 million in Q1 2026 per ALLO's latest filing, from -$50.9 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$50.9 million in Q4 2025 and troughed at -$224.9 million in Q3 2022.
- A 5-year average of -$100.6 million and a median of -$81.5 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2022 and 2025: Net Income towards Common Stockholders slumped 3379.13% in 2022, then soared 60.27% in 2025.
- Over 5 years, Net Income towards Common Stockholders stood at -$100.5 million in 2022, then rose by 27.55% to -$72.8 million in 2023, then increased by 21.0% to -$57.5 million in 2024, then advanced by 11.58% to -$50.9 million in 2025, then slumped by 185.38% to -$145.2 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$145.2 million, -$50.9 million, and -$65.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Allogene Therapeutics | 707.96 Mn | 707.96 Mn | - | -141.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -141.67 Mn |
| Mar 31, 2026 | -145.21 Mn |
| Dec 31, 2025 | -50.88 Mn |
| Sep 30, 2025 | -65.29 Mn |
| Jun 30, 2025 | -76.28 Mn |
| Mar 31, 2025 | -73.75 Mn |
| Dec 31, 2024 | -57.54 Mn |
| Sep 30, 2024 | -78.68 Mn |
| Jun 30, 2024 | -191.98 Mn |
| Mar 31, 2024 | -77.68 Mn |
| Dec 31, 2023 | -72.84 Mn |
| Sep 30, 2023 | -91.53 Mn |
| Jun 30, 2023 | -113.01 Mn |
| Mar 31, 2023 | -100.03 Mn |
| Dec 31, 2022 | -100.54 Mn |
| Sep 30, 2022 | -224.93 Mn |
| Jun 30, 2022 | -109.12 Mn |
| Mar 31, 2022 | -81.52 Mn |
| Dec 31, 2021 | 3.07 Mn |
| Sep 30, 2021 | -160.39 Mn |